Published in Probl Tuberk on January 01, 1999
Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein. Tuberculosis (Edinb) (2006) 0.84
[Combined therapy of pulmonary tuberculosis by using recombinant interleukins]. Probl Tuberk Bolezn Legk (2003) 0.77
[Effectiveness of new diagnostic drug Diaskintest in children for tuberculosis diagnostic]. Probl Tuberk Bolezn Legk (2009) 0.76
Effects of fullerene C60 nanocomposites on human platelet aggregation. Bull Exp Biol Med (2012) 0.75
[Immunotropic activity of antimicrobial agents used in tuberculosis]. Probl Tuberk (1996) 0.75
[Antihypoxic agents as drugs for pathogenetic therapy of tuberculosis (lecture)]. Probl Tuberk (1994) 0.75
[Activities of the Tuberculosis Chair of the Central Institute of Graduate Training of Physicians 1931-1980]. Probl Tuberk (1980) 0.75
[Tuberculin reactions in diagnosis and differential diagnosis of tuberculosis in children]. Pediatriia (1976) 0.75
[Problem of osteopoikilosis]. Klin Med (Mosk) (1993) 0.75
[Pharmacological characteristic of the product of condensation of phenamine with gamma-aminobutyric acid]. Farmakol Toksikol (1969) 0.75
[Comparative efficacy of clinical use of reamberin, remaxol and ademethionine in patients with tuberculosis of the respiratory organs and liver drug-injury]. Antibiot Khimioter (2013) 0.75
[Antihypoxant activity and mechanisms of action of some natural and synthetic compounds]. Eksp Klin Farmakol (2005) 0.75
[Diagnosis and treatment of urinary bladder dysfunctions in patients with nephrotuberculosis]. Urologiia (2007) 0.75
[Some directions in the prevention and therapy of cerebral hypoxia]. Zh Nevropatol Psikhiatr Im S S Korsakova (1973) 0.75
[Levamisole treatment of experimental tuberculosis]. Probl Tuberk (1981) 0.75
[Effectiveness of the combined use of antihypoxic agents and antioxidants in tuberculosis]. Probl Tuberk (1988) 0.75
[Pharmacological activity of runihol and S-adenosyl-L-methionine in rats with experimental liver damage by reserve antituberculosis drugs]. Eksp Klin Farmakol (2013) 0.75
[Changes in cerebral and erythrocyte ATP-ase activity in the presence of hypoxia and the influence of gutimine]. Farmakol Toksikol (1977) 0.75
[Effect of intraperitoneal grafting of the thymus on the course of experimental tuberculosis in guinea pigs]. Probl Tuberk (1978) 0.75
[Peculiarities of newly detected primary tuberculosis in children]. Pediatriia (1969) 0.75
[Activating effect of bestim on the macrophages in experimental tuberculosis of varying severity]. Probl Tuberk Bolezn Legk (2003) 0.75
[Course of sarcoidosis in childhood, adolescence and young adulthood]. Pediatriia (1982) 0.75
[Evaluation of the severity of tuberculous process in mouse lung]. Probl Tuberk (1993) 0.75
[Lymph node tuberculosis of the ductus arteriosus in children]. Probl Tuberk (1981) 0.75
[Effect of plasmapheresis on the course of experimental tuberculosis and the tolerance of chemotherapy by patients with renal tuberculosis]. Probl Tuberk (1992) 0.75
[On the action of pyridoxyphen on central nervous system]. Farmakol Toksikol (1968) 0.75
[Method of determining the activity of primary tuberculosis in children]. Probl Tuberk (1971) 0.75
[The hepatoprotective activity of remaxol and S-adenosyl-L-methionine for liver damage caused by reserve-series antituberculosis drugs]. Arkh Patol (2013) 0.75
[Difficulties in diagnosing minor forms of primary intrathoracic tuberculosis in children]. Probl Tuberk (1980) 0.75
[The structure and antihypoxic action of alpha-dicarbonyl compounds and their derivatives]. Farmakol Toksikol (1978) 0.75
[Evaluation of the hepatotoxicity of isoniazid using the bromsulphalein test in animal experiments]. Probl Tuberk (1983) 0.75
[Morphologic characteristics of pathological changes in the lungs in experimental tuberculosis in rats with immunodeficiency, and its correction]. Probl Tuberk (1984) 0.75
[Anti-tuberculous activity of amikacin]. Probl Tuberk (1986) 0.75
[The hepatotropic activity of runihol and ademethionine against experimental liver damage caused by first-line antituberculosis drugs]. Arkh Patol (2014) 0.75
[Preclinical and clinical trials of the new tuberculosis drug perchlozon]. Ter Arkh (2016) 0.75
[Increase of resistance of the myocardium to acute hypoxia by means of gutimine]. Farmakol Toksikol (1969) 0.75
[Immunotropic and antihypoxant therapy of experimental drug-sensitive and drug-resistant tuberculosis]. Patol Fiziol Eksp Ter (2013) 0.75
[The effectiveness of influenza vectors expressing the protective mycobacterial antigen ESAT-6 in the complex therapy of generalized tuberculosis in mice]. Probl Tuberk Bolezn Legk (2008) 0.75
[Development of an experimental tuberculous process in the presence of immune deficiency and immunostimulation]. Biull Eksp Biol Med (1981) 0.75
[The role of T-cell immunity in tuberculosis resistance in rats]. Probl Tuberk (1983) 0.75
[The influence of immunotropic drugs on reparative processes in the lungs experimental chemotherapy drug resistant tuberculosis]. Eksp Klin Farmakol (2014) 0.75
[Efficacy of immunotropic drugs in experimental tuberculosis]. Probl Tuberk (1985) 0.75
[Characteristics of intrathoracic tuberculosis in children]. Probl Tuberk (1982) 0.75
[H-cholinolytic activity of new bis-ammonium compounds]. Farmakol Toksikol (1968) 0.75
[Comparative study of hepatoprotective action of remaxol, reamberin and ademethionine in liver injury induced by antituberculosis drugs (experimental study)]. Antibiot Khimioter (2011) 0.75
[Influence exerted by adreno- and sympatholytic agents on changes of primary responses in the visual cortex induced by lysergic acid diethylamide]. Farmakol Toksikol (1966) 0.75
[Effectiveness and mechanism of action of a new plant complex drug in nonspecific inflammatory processes in the bronchopulmonary system]. Patol Fiziol Eksp Ter (2003) 0.75
[Cephalosporins as possible methods of etiotropic therapy of tuberculosis]. Probl Tuberk (1993) 0.75
[Exudative pleurisy in children]. Probl Tuberk (1979) 0.75
[Hepatotropic therapy in treatment of liver injury]. Antibiot Khimioter (2012) 0.75
[Prevention of tuberculosis: current approaches to development of vaccines]. Vestn Ross Akad Med Nauk (2012) 0.75
[Sodium metabisulfite inhibition of the reaction between isoniazid and streptomycin in solution]. Probl Tuberk (1983) 0.75
[Enhancement of the activity of antitubercular agents with other antimicrobial agents]. Probl Tuberk (1994) 0.75
[History of St. Petersburg Research Institute of Phthisiopulmonology, Ministry of Health of Russia]. Probl Tuberk Bolezn Legk (2003) 0.75
[Changes in the intensity of anaerobic carbohydrate metabolism under the influence of gutimine]. Farmakol Toksikol (1973) 0.75
[Destructive tuberculosis of the lung in adolescents]. Probl Tuberk (1977) 0.75
[Effect of various methods of immunotherapy on the immunological status of patients with pulmonary tuberculosis]. Probl Tuberk (1984) 0.75
[Extrathoracic and disseminated sarcoidosis in children, teenagers, and adolescents]. Probl Tuberk (1982) 0.75
[The effect of runihol and exogenous S-adenosyl-L-methionine on the morphological pattern of the liver upon hepatotoxic exposure to reserve-series antituberculous drugs]. Arkh Patol (2013) 0.75
[Differential diagnosis of disseminated pulmonary tuberculosis in children]. Probl Tuberk (1977) 0.75
[Comparative study of remaxol and ademethionine effects on reparative regeneration processes in the liver subjected to surgical intervention]. Eksp Klin Farmakol (2011) 0.75
[Reparative osteogenesis after incorporation of roncoleukin into therapy for experimental tuberculous gonitis]. Arkh Patol (2014) 0.75
[Cytokine production during the development and correction of an immunodeficiency in experimental tuberculosis]. Probl Tuberk (1996) 0.75
[Effect of riboxine, levamisole and sodium oxybutyrate on the course of experimental tuberculosis]. Probl Tuberk (1988) 0.75
Effect of gutimin on lactic acid utilization. Bull Exp Biol Med (1974) 0.75
[Experimental model of combined pathology of tuberculosis-opisthorchiasis]. Patol Fiziol Eksp Ter (1994) 0.75
[The epidemiologic significance of the resistance of tuberculosis mycobacteria to isonicotinic acid hydrazide]. Probl Tuberk (1971) 0.75
[Use of deoxyribonuclease in the treatment of experimental tuberculosis]. Probl Tuberk (1981) 0.75
[A role of the HLA-DRB1* genotype in the complex therapy of pulmonary tuberculosis]. Probl Tuberk Bolezn Legk (2008) 0.75
[The results of the use of riboxin in the combined treatment of patients with pulmonary tuberculosis]. Probl Tuberk (1989) 0.75
[Training of high-skilled researchers at the Saint-Petersburg Research Institute of Phtisiopulmonology in 1994-1998]. Probl Tuberk (1999) 0.75
[New approaches to the treatment of mycobacterioses of the lungs]. Probl Tuberk (1991) 0.75
[Investigation of remaxol efficacy in complex therapy of experimental generalized tuberculosis on mice]. Antibiot Khimioter (2012) 0.75
[Chemotherapy of experimental mycobacteriosis]. Probl Tuberk (1988) 0.75
[Effect of acute hypoxic hypoxia on rat liver mitochondrial respiration]. Vopr Med Khim (1981) 0.75
[Elastic materials in surgery for inflammatory diseases of the vertebral column]. Probl Tuberk Bolezn Legk (2006) 0.75
[Use of dimephosphon in pathogenetic therapy of experimental tuberculosis]. Probl Tuberk (1991) 0.75
[Experimental and clinical study of preparation Iridol action on the central nevros system]. Eksp Klin Farmakol (2006) 0.75
[An experimental study of the efficiency of cycloferon in the complex chemotherapy of generalized drug-resistant tuberculosis]. Eksp Klin Farmakol (2012) 0.75